Plasma Protein Products Market Growth and Key Drivers
The plasma protein products market, valued at USD 32.8 billion in 2023, is projected to reach USD 72.9 billion by 2034, growing at a CAGR of 7.53%. This growth is fueled by rising cases of hematological and autoimmune disorders, increased research efforts, and greater awareness of plasma donation.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5305
Plasma Protein Products Market: From Blood to Biotech
Plasma, which makes up about 55% of blood, is the source of plasma protein products. These products are extracted through a process called fractionation, where large volumes of plasma are processed into smaller amounts of finished products. Examples include albumin, coagulation factors, fibrinolytic proteins, immunoglobulin, and clotting factors.
The growing prevalence of hematological and immunological disorders is driving the demand for plasma protein products. These products are essential in treating conditions such as bleeding disorders, trauma, hemorrhages, and coagulation deficiencies. Additionally, increased awareness of blood donations and advancements in fractionation techniques are further boosting market growth.
Top Companies in the Plasma Protein Products Market
- ADMA Biologics, Inc.
ADMA Biologics is a leading biopharmaceutical company that specializes in the development, manufacturing, and commercialization of plasma-derived therapies. Their portfolio includes immunoglobulins and other plasma protein-based treatments for immune deficiencies and other critical conditions. - BioLife
BioLife is a prominent provider of high-quality biopharmaceuticals, particularly focusing on the collection and manufacturing of plasma-derived products. The company plays a key role in producing proteins used to treat bleeding disorders, immune system deficiencies, and other diseases. - Bio Products Laboratory (BPL)
Based in the UK, BPL is a global leader in the development and supply of high-quality plasma protein products. The company specializes in producing immunoglobulins, clotting factor concentrates, and other therapeutic proteins used to treat rare and chronic conditions. - China Biologic Products
China Biologic Products is one of the largest players in the plasma protein products market in China. The company is involved in the collection, processing, and distribution of human plasma-derived products, including immunoglobulin and clotting factors. - CSL Behring
CSL Behring, a subsidiary of CSL Limited, is a global biotechnology company that manufactures plasma-derived therapies for treating bleeding disorders, immune deficiencies, and other serious health conditions. CSL Behring is renowned for its innovative products and has a strong presence in the global plasma protein products market. - Grifols S.A.
Grifols is a Spanish multinational company that specializes in the production of plasma-derived medicines. It is one of the world’s leading providers of immunoglobulin therapies, coagulation factors, and other plasma proteins used in the treatment of hematological and immune disorders. - Kedrion Biopharma
Kedrion Biopharma is an international biopharmaceutical company focused on the production of plasma-derived products. With a wide range of therapeutic products, Kedrion is a significant player in treating bleeding disorders, immunodeficiencies, and other conditions through its plasma-based therapies. - LFB Group
LFB Group is a global biotechnology company that specializes in producing plasma-derived products, including immunoglobulin, clotting factors, and other proteins. LFB’s therapies are critical for the treatment of various immunological and bleeding disorders. - Octapharma
Octapharma is an international human protein manufacturer, specializing in the production of plasma protein products. The company’s offerings include treatments for bleeding disorders, immune deficiencies, and other conditions that require plasma-derived therapies. - PlasmaGen Biosciences
PlasmaGen Biosciences focuses on the development of innovative plasma-derived therapies for treating a wide range of diseases, particularly bleeding disorders and immune deficiencies. The company is committed to advancing the medical applications of plasma proteins. - Sanquin
Sanquin is a non-profit organization based in the Netherlands, responsible for the collection, processing, and supply of blood and blood products. It is one of the key suppliers of plasma-derived therapies, focusing on immunoglobulins, clotting factors, and other essential proteins. - Takeda Pharmaceuticals
Takeda Pharmaceuticals is a multinational pharmaceutical company that produces a range of plasma-derived therapies. Known for its treatments for hemophilia, immunodeficiencies, and other chronic conditions, Takeda’s plasma products are integral to global healthcare.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/plasma-protein-products-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5305
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare